Format

Send to

Choose Destination
BMC Res Notes. 2015 Sep 28;8:484. doi: 10.1186/s13104-015-1405-4.

ABCG2 impairs the activity of the aurora kinase inhibitor tozasertib but not of alisertib.

Author information

1
Institut für Medizinische Virologie, Klinikum der Goethe-Universität, Paul Ehrlich-Str. 40, 60596, Frankfurt Am Main, Germany. M.Michaelis@kent.ac.uk.
2
Centre for Molecular Processing and School of Biosciences, University of Kent, Canterbury, CT2 7NJ, UK. M.Michaelis@kent.ac.uk.
3
Institut für Medizinische Virologie, Klinikum der Goethe-Universität, Paul Ehrlich-Str. 40, 60596, Frankfurt Am Main, Germany. f.selt@dkfz.de.
4
Deutsches Krebsforschungszentrum (DKFZ), Klinische Kooperationseinheit Pädiatrische Onkologie (G340) and Pädiatrie III, Zentrum für Kinder- und Jugendmedizin, Im Neuenheimer Feld 280, 69120, Heidelberg, Germany. f.selt@dkfz.de.
5
Institut für Medizinische Virologie, Klinikum der Goethe-Universität, Paul Ehrlich-Str. 40, 60596, Frankfurt Am Main, Germany. f.rothweiler@kinderkrebsstiftung-frankfurt.de.
6
Pharmaceutical Institute, University of Bonn, An der Immenburg 4, 53121, Bonn, Germany. mwiese@uni-bonn.de.
7
Institut für Medizinische Virologie, Klinikum der Goethe-Universität, Paul Ehrlich-Str. 40, 60596, Frankfurt Am Main, Germany. Cinatl@em.uni-frankfurt.de.

Abstract

BACKGROUND:

Recently, we have shown that the ATP-binding cassette (ABC) transporter ABCB1 interferes with the anti-cancer activity of the pan-aurora kinase inhibitor tozasertib (VX680, MK-0457) but not of the aurora kinase A and B inhibitor alisertib (MLN8237). Preliminary data had suggested tozasertib also to be a substrate of the ABC transporter ABCG2, another ABC transporter potentially involved in cancer cell drug resistance. Here, we studied the effect of ABCG2 on the activity of tozasertib and alisertib.

RESULTS:

The tozasertib concentration that reduces cell viability by 50% (IC50) was dramatically increased in ABCG2-transduced UKF-NB-3(ABCG2) cells (48.8-fold) compared to UKF-NB-3 cells and vector-transduced control cells. The ABCG2 inhibitor WK-X-34 reduced tozasertib IC50 to the level of non-ABCG2-expressing UKF-NB-3 cells. Furthermore, ABCG2 depletion from UKF-NB-3(ABCG2) cells using another lentiviral vector expressing an shRNA against the bicistronic mRNA of ABCG2 and eGFP largely re-sensitised these cells to tozasertib. In contrast, alisertib activity was not affected by ABCG2 expression.

CONCLUSIONS:

Tozasertib but not alisertib activity is affected by ABCG2 expression. This should be considered within the design and analysis of experiments and clinical trials investigating these compounds.

PMID:
26415506
PMCID:
PMC4587578
DOI:
10.1186/s13104-015-1405-4
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center